Halozyme Therapeutics Inc. (HALO)
BMV
Closed
Oct 8, 2026
Day's Range
1,968.6952 wk Range
1,121.86Overview - HALO - Halozyme Therapeutics Inc.
Key Statistics
Valuation
Enterprise Value
3.60T
P/E (Trailing)
‪30.67‬
PEG Ratio
‪0.69‬
Price / Sales (TTM)
‪123.40‬
Price / Book
‪84.33‬
EV / EBITDA
‪197.26‬
Profitability
Gross Margin
‪83.54%‬
Profit Margin
‪24.85%‬
Operating Margin
‪59.80%‬
Return on Assets
‪25.49%‬
Return on Equity
‪173.67%‬
Ownership
Shares Outstanding
114.04M
Float
112.18M
Held by Insiders
‪1.10%‬
Held by Institutions
‪112.14%‬
Price stats
Beta
‪0.88‬
50-Day Avg
‪1,630.42‬
200-Day Avg
‪1,325.15‬
Dividends
Payout Ratio
‪0.00%‬
Market Cap - HALO - Halozyme Therapeutics Inc.
Peers - HALO - Halozyme Therapeutics Inc.
Peer Comparison
Compared with companies in Biotechnology listed on BMV.
- HALOBMVHalozyme Therapeutics Inc.205.31BMarket Cap+37.98%52-week change30.68P/E (Trailing)‪24.85%‬Profit Margin
- ARGXNBMVargenx SE American Depositary Receipt1.05TMarket Cap+10.77%52-week change36.36P/E (Trailing)‪32.26%‬Profit Margin
- ALNYBMVAlnylam Pharmaceuticals, Inc.742.50BMarket Cap-51.02%52-week change53.47P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNBMVBioNTech SE American Depositary Share413.38BMarket Cap-18.50%52-week change1.65P/E (Trailing)‪-63.63%‬Profit Margin
- ASND1NBMVAscendis Pharma A/S291.08BMarket Cap+3.50%52-week change19.80P/E (Trailing)‪70.84%‬Profit Margin
- BMRNBMVBioMarin Pharmaceutical Inc.213.89BMarket Cap+10.22%52-week change172.39P/E (Trailing)‪2.14%‬Profit Margin
- AGIOBMVAgios Pharmaceuticals, Inc.72.95BMarket Cap+0.00%52-week change5.17P/E (Trailing)‪88.25%‬Profit Margin
Profile Summary - HALO - Halozyme Therapeutics Inc.
About
Halozyme Therapeutics Inc. is a biopharmaceutical technology company focused on drug delivery solutions and specialty medicines. Its core platform, ENHANZE, uses the proprietary enzyme rHuPH20 to help enable subcutaneous delivery of injectable therapies and fluids, supporting more convenient administration and…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
